# Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1

Source: https://onco.cc/trials/nct07040436/  
OnCo record `nct07040436` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of OPM-101 run by Oncodesign Precision Medicine, not yet recruiting.

## Summary

Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1 is a phase 1/2 interventional study registered as NCT07040436 by Oncodesign Precision Medicine, with 41 participants planned, started 2025-09. Conditions recorded: Advanced Melanoma. Interventions recorded: OPM-101.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07040436
- Phase: 1/2
- Setting: REVERT Study: A Phase 1b/2a Study to Assess the Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1
- Sponsor: Oncodesign Precision Medicine
- Enrolled: 41

## Sources

- ClinicalTrials.gov NCT07040436: https://clinicaltrials.gov/study/NCT07040436

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [OPM-101](https://onco.cc/drugs/opm-101/)
- companies: [Oncodesign Precision Medicine](https://onco.cc/companies/oncodesign-precision-medicine/)

---
JSON: https://onco.cc/api/v1/entities/nct07040436.json